Third Rock Ventures’ Post

It is my pleasure to announce that I am joining the strong team at Terremoto Biosciences as its chief executive officer to transform patient care through science. I am honored to lead the efforts at Terremoto, inspired by the great team and vast potential of our work and united in our mission to develop highly targeted, small-molecule medicines with superior therapeutic benefits. Read more about my exciting next endeavor in the article below. For additional information, read our press release here: https://lnkd.in/gh6QF6Nc

Congratulations to Stanford University School of Medicine investigators on the first peer-reviewed publication of their Phase 1 clinical study evaluating our lead candidate CD22 CAR T-cell therapy, firi-cel, in the The Lancet! These impactful findings continue to demonstrate the curative potential of firi-cel and support the study design of our currently enrolling Phase 2 program. Learn more: https://lnkd.in/dH_QQNmK #CART #celltherapy

We’re excited to announce IND clearance of ABA-101 for Progressive Multiple Sclerosis (MS). It’s the first open IND for our best-in-class autologous TCR-Treg cell therapy platform. We expect to initiate our Phase 1 study later this year. This is an important milestone for us and for patients. ABA-101 was specifically designed to benefit Progressive MS patients who have no or insufficient treatment options today. bit.ly/3LiotOa

Introducing Marea – a clinical-stage biotech on a mission to leverage large-scale human genetics and adipose biology to revolutionize the treatment of #cardiometabolic diseases. Cardiovascular disease remains the number one killer in the U.S. and globally despite many advances over the past few decades. With a clinical-stage pipeline of first-in-class treatments and a team of some of the industry’s most dynamic scientists and company builders, we’re ready to take this challenge head on. Learn more about Marea in the release below or visit us at www.mareatx.com. https://lnkd.in/eM5MrHtD

We are so excited today to announce the pricing of our Initial Public Offering (IPO). We believe this important milestone will position us well as we look to further invest in our pipeline and advance our vision of transforming the lives of patients with CNS disorders. We expect shares of Rapport to start trading on Nasdaq Exchange tomorrow under the ticker symbol “RAPP”. Today would not have been possible without the relentless determination and commitment of our incredible team of Rapptors. Thank you! https://bit.ly/3yYDQZ0 #IPO #Innovation #BostonBiotech #Biotech